top of page

R&A PSYINS Issues “Psychedelic Medicine Year-End Analysis and 2024 Outlook” Report"

R&A PSYINS released its Psychedelic Medicine Year-End Analysis and 2024 Outlook: “Navigating the Opportunities, Challenges and Unique Risks of Providing Breakthrough Treatments.” Produced in partnership with Neuly and Psychedelic Invest, the report discusses the catalysts that could propel the industry forward, emerging opportunities and challenges, and the role insurance will play in ensuring the long-term viability and success of psychedelic ventures.


From local ballots to Capitol Hill, 2024 is shaping up to be an important year for psychedelic drug policy reform.  The regulatory landscape will play a crucial role in defining the future of the industry and unlocking new opportunities. This landmark report seeks to address a paramount issue facing psychedelic medicinal businesses. While more state legislators are pushing forward psychedelic policy reform – opening the door for more therapists and clinicians, retreats, and investors to enter the space – it has been difficult for psychedelic medicinal businesses to access insurance in this current hardened insurance market, leaving them exposed to a wide spectrum of risks.


 “As psychedelic-assisted therapies progress from the margins to the mainstream, the risks only increase.” said Eric Rahn, Managing Director. “Insurance will play a key role in ensuring the long-term viability and success of psychedelic ventures. The good news is there are more options by the day for accessing critical coverages to protect licensed practitioners and businesses from medical malpractice and other damaging claims.”


To access the report, click on the link below:


. 


If you have questions regarding insurance coverages or would like a detailed risk assessment and analysis, please click here for a free consultation or email eric@rahn-associates.com.



bottom of page